Aquestive Therapeutics Inc. (AQST) is scheduled to present multiple presentations highlighting results from the investigational use of its product candidate Anaphylm sublingual film in the treatment of severe allergic reactions, including anaphylaxis, at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting on November 7, 2025.
Anaphylm sublingual film, the company's lead asset, is the first and only non-device-based, orally delivered epinephrine product candidate for the proposed treatment of anaphylaxis, a rapid-onset, life-threatening allergic reaction requiring immediate intervention.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com